Hügel T, Zöls S, Palzer A, Kaufmann S, Langhoff R, Ritzmann M, Heinritzi K
Klinik für Schweine, Ludwig-Maximilians-Universität München, Oberschleißheim.
Tierarztl Prax Ausg G Grosstiere Nutztiere. 2011;39(6):353-7.
The effects of vaccination against gonadotropin releasing factor (GnRF) with Improvac® (Pfizer Animal Health) were compared with surgical castration in fattening pigs.
A total of 205 pigs were surgically castrated (group K) and 191 were vaccinated twice (group V) using the boar taint vaccine (Improvac®; 2ml s.c.). The first dose was administered atthe age of 12 weeks when the animals were moved into the fattening unit and the second dose in week 18, 4-6 weeks before the planned slaughter date. Live weights were recorded in weeks 1, 4, 12, 18, and 22. In weeks 18 and 20, length and width of the testicles of 171 animals of group V were measured. After slaughtering cold carcass weight, back fat depth, muscle thickness, percent lean meat, and fat and muscle areas of the carcasses were determined. A piece of the neck muscle from each pig was used to conduct a cooking and melting sensory test.
While no significant weight difference was evident in week 22 (K=89.4kg; V=88.6kg), cold carcass weight, and back fat and muscle thickness were lower for vaccinates. Vaccinates had higher average daily weight gains (ADW) after the second injection from week 18 up to the cut-off weighing in week 22 (V=1121g; K=1007g; p<0.001) in contrast to average daily weight gains between weeks 12 and 18 (K=740g; V=668g; p<0.001). After the second injection, testicle size of vaccinated pigs decreased significantly. All animals were negative for boar taint by both cooking and melting tests.
Boars vaccinated against boar taint had lower ADW before the second vaccination, but compensated the weight difference after complete vaccination. The significant reduction in the testicle size after the second injection indicates a vaccination success. After vaccination no boar taint was detected in carcasses.
Vaccination as well as surgical castration reliably prevents the incidence of boar taint. The late rise in daily gain can be beneficial if management is aligned.
比较使用英普罗瓦克(Improvac®,辉瑞动物保健公司生产)接种促性腺激素释放因子(GnRF)疫苗与对育肥猪进行手术去势的效果。
共205头猪接受手术去势(K组),191头猪使用公猪异味疫苗(英普罗瓦克®;2毫升皮下注射)进行两次接种(V组)。首剂在动物12周龄转入育肥舍时接种,第二剂在第18周接种,即在计划屠宰日期前4 - 6周。在第1、4、12、18和22周记录活重。在第18周和第20周,测量V组171头动物的睾丸长度和宽度。屠宰后测定冷胴体重、背膘厚度、肌肉厚度、瘦肉率以及胴体的脂肪和肌肉面积。从每头猪颈部取一块肌肉进行烹饪和融化感官测试。
在第22周时体重无显著差异(K组 = 89.4千克;V组 = 88.6千克),但接种疫苗的猪冷胴体重、背膘和肌肉厚度较低。与第12周和第18周之间的平均日增重(K组 = 740克;V组 = 668克;p < 0.001)相比,接种疫苗的猪在第18周第二次注射后至第22周截止称重期间平均日增重更高(V组 = 1121克;K组 = 1007克;p < 0.001)。第二次注射后,接种疫苗的猪睾丸大小显著减小。通过烹饪和融化测试,所有动物的公猪异味均呈阴性。
接种预防公猪异味疫苗的公猪在第二次接种前平均日增重较低,但在完全接种后弥补了体重差异。第二次注射后睾丸大小显著减小表明疫苗接种成功。接种疫苗后胴体未检测到公猪异味。
接种疫苗以及手术去势均能可靠地预防公猪异味的发生。如果管理得当,后期日增重的增加可能有益。